ARQT - NASDAQ
Arcutis Biotherapeutics, Inc.
$21.35
-0.56%Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
At a Glance
Live SnapshotArcutis Biotherapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Arcutis Biotherapeutics, Inc. Income Statement
ARQT • NASDAQ
| Arcutis Biotherapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||
376.1M | 196.5M | 59.6M | 3.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||
(36.7M) | (19.1M) | (5M) | (754K) | (763K) | (455K) | (195K) | (0.0) | (0.0) | |
339.4M | 177.4M | 54.6M | 2.9M | -763K | -455K | -195K | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||
(351.6M) | (305.8M) | (295.7M) | (304.6M) | (205.8M) | (136.2M) | (42.9M) | (19.7M) | (4.1M) | |
(274.6M) | (229.4M) | (185.1M) | (122.1M) | (61M) | (20.9M) | (6.4M) | (1.8M) | (695K) | |
(77.1M) | (76.4M) | (110.6M) | (182.4M) | (145.6M) | (115.3M) | (36.5M) | (17.9M) | (3.4M) | |
-12.2M | -128.4M | -241.1M | -301.6M | -206.5M | -136.6M | -43.1M | -19.7M | -4.1M | |
PRE-TAX INCOME | |||||||||
(12.1M) | (27.2M) | (29.7M) | (15.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-12.1M | -27.2M | -29.7M | -15.7M | 173K | 967K | 1.1M | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (173K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-2.7M | -11M | -17.9M | -9.8M | 173K | 967K | 1.1M | 480K | -872K | |
-15M | -139.4M | -259M | -311.5M | -206.4M | -135.7M | -42M | -19.3M | -5M | |
NET INCOME | |||||||||
(1.2M) | (647K) | (3.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-16.1M | -140M | -262.1M | -311.5M | -206.4M | -135.7M | -42M | -19.3M | -5M |
SEC Filings
ARQT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 03, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 28, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | August 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 06, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your ARQT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.